Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oncology Pharma Inc (OP: ONPH )

0.0001 UNCHANGED
Streaming Delayed Price Updated: 2:17 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Oncology Pharma Inc

World Awaits Bankman-Fried Sentence, Drug Stock Pump-And-Dump, Penny Stock Fraud: Financial Crimes Weekly
Prosecutors push for harshest punishment for Sam Bankman-Fried, convicted on fraud charges in FTX collapse. Defense seeks leniency. 
Via Benzinga
Topics Fraud Lawsuit
Exposures Criminal Legal
Oncology Pharma Conducting Interviews and Presentations with Investors to Pursue Next Steps to Forward The Development Process of Nanoemulsion Drug Delivery System
SAN FRANCISCO, CA / ACCESSWIRE / July 12, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is furthering progress in discussions with investors and developing the... 
From Oncology Pharma Inc.
Via AccessWire
Oncology Pharma Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery System
SAN FRANCISCO, CA / ACCESSWIRE / June 29, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to be reviewing the financing for taking the steps on moving... 
From Oncology Pharma Inc.
Via AccessWire
Exposures Product Safety
Oncology Pharma Announces: Initial Feasibility Study of the Nanoemulsion Drug Delivery System is Complete and Results Have Met the Threshold for Moving Forward To the Next Steps of Development
SAN FRANCISCO, CA / ACCESSWIRE / June 8, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased that the initial feasibility stage is complete and results have... 
From Oncology Pharma Inc.
Via AccessWire
Oncology Pharma Advances Progress on Multiple Fronts Including Advanced Attention to Connect2Trials' Commercial Development
SAN FRANCISCO, CA / ACCESSWIRE / May 9, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to execute its next phase with Connect2Trials, Inc. Originally,... 
From Oncology Pharma Inc.
Via AccessWire
Oncology Pharma Completes Feasibility Phase of its Licensed Nanoemulsion Drug Delivery System to Treat Cancer
SAN FRANCISCO, CA / ACCESSWIRE / April 13, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma ("The Company") is pleased to announce that it has completed the initial feasibility phase of its... 
From Oncology Pharma Inc.
Via AccessWire
Oncology Pharma Reports on Progress with Ribera Solutions
SAN FRANCISCO, CA / ACCESSWIRE / March 2, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to announce progress with its investment with Ribera Solutions'... 
From Oncology Pharma Inc.
Via AccessWire
Oncology Pharma Releases Further Feasibility Studies, Data and Capacities
SAN FRANCISCO, CA / ACCESSWIRE / February 23, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") looks toward releasing further results of the studies under the... 
From Oncology Pharma Inc.
Via AccessWire
Oncology Pharma Expands on Feasibility Studies and Data
SAN FRANCISCO, CA / ACCESSWIRE / February 17, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") wants to expand on a previously announced press release that included... 
From Oncology Pharma Inc.
Via AccessWire
Oncology Pharma, Inc. and Regen BioPharma, Inc. Announce Intent to Jointly Fast Track Development of Modified mRNA anti-Cancer Vaccine
SAN FRANCISCO, CA / ACCESSWIRE / February 14, 2022 / Oncology Pharma, Inc. ("The Company") (OTC PINK:ONPH) and Regen BioPharma, Inc. (OTC PINK:RGBP) and (OTC PINK:RGBPP): announced that they intend to... 
From Oncology Pharma Inc.
Via AccessWire
Oncology Pharma Gives Update on Technology, Formulation and Data Creation
SAN FRANCISCO, CA / ACCESSWIRE / February 8, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to announce that the co-development agreement and ongoing... 
From Oncology Pharma Inc.
Via AccessWire
Oncology Pharma's New Year Update
SAN FRANCISCO, CA / ACCESSWIRE / January 10, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") update on its progress to kick off the new year. The Company has... 
From Oncology Pharma Inc.
Via AccessWire
Oncology Pharma Meeting Towards Future Developments
SAN FRANCISCO, CA / ACCESSWIRE / December 17, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. ("The Company") conducted a meeting with the Board of Directors, executives, and... 
From Oncology Pharma Inc.
Via AccessWire
Oncology Pharma Year End Review and Outlook
SAN FRANCISCO, CA / ACCESSWIRE / December 9, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") and its Chief Executive are pleased to give a year end update and... 
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Oncology Pharma Research and Vision
SAN FRANCISCO, CA / ACCESSWIRE / November 30, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is a pioneering oncology company dedicated to providing the financing... 
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Oncology Pharma Reveals Plans for Development of Lead Cancer Drug Candidate
SAN FRANCISCO, CA / ACCESSWIRE / November 8, 2021 / Oncology Pharma, Inc. (the "Company") is pleased to provide some insight into the progress of its co-development project with NanoSmart... 
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Oncology Pharma, Inc. Gives Update on Ongoing Work and Progress
SAN FRANCISCO, CA / ACCESSWIRE / October 27, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Pursuant to previous communications, Oncology Pharma, Inc. (the "Company") is making progress towards pursuing... 
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Oncology Pharma, Inc. Has Engaged a PCAOB Audit Firm Looking Towards Moving the Company Towards a Senior Listing
SAN FRANCISCO, CA / ACCESSWIRE / October 15, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Pursuant to previously announced press release, Oncology Pharma, Inc. (the "Company") has retained the services... 
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures Intellectual Property Legal Regulatory
Oncology Pharma, Inc. Update on PCAOB Audit Selection Process and License Agreement
SAN FRANCISCO, CA / ACCESSWIRE / October 12, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") would like to update investors on its progress. The Company is in the... 
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Oncology Pharma, Inc. Has Received the Committed Funding to Perform All Necessary IND-Enabling Preclinical Work for Its First Lead Candidate, a Dactinomycin Nanoemulsion Drug Product
SAN FRANCISCO, CA / ACCESSWIRE / September 13, 2021 / Oncology Pharma, Inc. (OTC PINK:ONPH). In keeping with management's commitment to continue implementation of Oncology Pharma's ("the Company")... 
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Oncology Pharma's Co-Development Agreement Pursues Strategic and Direct Objectives
SAN FRANCISCO, CA / ACCESSWIRE / August 23, 2021 / Oncology Pharma, Inc. (OTC PINK:ONPH) defines its objective and strategy for recently signed Co-Development deal. The primary goal of the... 
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Oncology Pharma, Inc. Executes Co-Development Agreement with NanoSmart Pharmaceuticals, Inc.
SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) With much anticipation, Oncology Pharma, Inc. has finalized a Co-Development Agreement with NanoSmart... 
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Oncology Pharma, Inc. To Move to Conducting Trials on Licensed IP
SAN FRANCISCO, CA / ACCESSWIRE / July 20, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") is laying out and taking necessary steps to move its licensed IP forward.... 
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Oncology Pharma, Inc. is Entering Into the Next Phase of its Growth and Expansion Phase
SAN FRANCISCO, CA / ACCESSWIRE / June 30, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") is developing a program to establish the use of its license utilizing NR2F6... 
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Oncology Pharma, Inc. Eyes Collaboration with Patent Opportunities Amongst Its Licensed Intellectual Properties
SAN FRANCOSCO, CA / ACCESSWIRE / June 15, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the 'Company') has been continuing its research and work reviewing and implementing... 
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Oncology Pharma and Ribera Solutions Release White Paper Regarding Patient Engagement and Retention Platform
SAN FRANCISCO, CA / ACCESSWIRE / June 9, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the 'Company') is releasing a White Paper outlining 5 innovative ways to improve patient... 
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Oncology Pharma, Inc. Is Pursuing the Development of Its Small Molecule Drug for the Treatment of Colon Cancer
SAN FRANCISCO, CA / ACCESSWIRE / May 18, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") is pursuing, through its licensing arrangements, the development of a small... 
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Oncology Pharma, Inc. Has Submitted Its Initial Application to List the Company on the Capital Markets Tier of the NASDAQ Exchange
SAN FRANCISCO, CA / ACCESSWIRE / May 12, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") has submitted its initial application to the NASDAQ to begin the process of... 
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Oncology Pharma Enters into License Agreement for Small Molecules Intellectual Property for the Treatment of Colon Cancer
SAN FRANCISCO, CA / ACCESSWIRE / May 7, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) ONPH has entered into a licensing agreement with Regen BioPharma, Inc. for a technology utilizing small molecules to... 
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Oncology Pharma, Inc. Prepares Plan Toward Funding Development and Implementation of Ribera Solutions' Patient Engagement and Retention Platform
SAN FRANCISCO, CA / ACCESSWIRE / April 21, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") is moving ahead with advancing its efforts with Ribera Solutions' Conect2Med... 
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.